Exelixis
EXEL
#1827
Rank
ยฃ8.66 B
Marketcap
ยฃ32.32
Share price
-1.20%
Change (1 day)
10.11%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2024: ยฃ1.72 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is ยฃ1.69 Billion. In 2024 the company made a revenue of ยฃ1.72 Billion an increase over the revenue in the year 2023 that were of ยฃ1.43 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2024

Annual revenue

Year Revenue Change
2024ยฃ1.72 B20.3%
2023ยฃ1.43 B7.88%
2022ยฃ1.33 B25.27%
2021ยฃ1.06 B46.73%
2020ยฃ0.72 B-1.83%
2019ยฃ0.73 B9.72%
2018ยฃ0.67 B100.91%
2017ยฃ0.33 B115.77%
2016ยฃ0.15 B518.57%
2015ยฃ25.08 M55.52%
2014ยฃ16.12 M-15.1%
2013ยฃ18.99 M-35.29%
2012ยฃ29.35 M-84.25%
2011ยฃ0.18 B55.46%
2010ยฃ0.11 B27.82%
2009ยฃ93.78 M16.62%
2008ยฃ80.41 M40.79%
2007ยฃ57.11 M13.39%
2006ยฃ50.37 M14.36%
2005ยฃ44.04 M59.99%
2004ยฃ27.53 M-4.44%
2003ยฃ28.81 M4.23%
2002ยฃ27.64 M-2.26%
2001ยฃ28.28 M70.49%
2000ยฃ16.58 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Johnson & Johnson
JNJ
ยฃ68.26 B 3,927.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ46.50 B 2,643.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
ยฃ26.64 B 1,472.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
ยฃ35.20 B 1,976.95%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
ยฃ47.58 B 2,707.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ35.58 B 1,999.19%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
ยฃ31.37 B 1,750.91%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
ยฃ8.62 M-99.49%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
ยฃ69.86 M-95.88%๐Ÿ‡บ๐Ÿ‡ธ USA